Literature DB >> 22577615

Therapy of gallstone disease: What it was, what it is, what it will be.

Piero Portincasa1, Agostino Di Ciaula, Leonilde Bonfrate, David Qh Wang.   

Abstract

Cholesterol gallstone disease is a common clinical condition influenced by genetic factors, increasing age, female gender, and metabolic factors. Although laparoscopic cholecystectomy is currently considered the gold standard in treating patients with symptomatic gallstones, new perspectives regarding medical therapy of cholelithiasis are currently under discussion, also taking into account the pathogenesis of gallstones, the natural history of the disease and the analysis of the overall costs of therapy. A careful selection of patients may lead to successful non-surgical therapy in symptomatic subjects with a functioning gallbladder harboring small radiolucent stones. The classical oral litholysis by ursodeoxycholic acid has been recently paralleled by new experimental observations, suggesting that cholesterol-lowering agents which inhibit cholesterol synthesis (statins) or intestinal cholesterol absorption (ezetimibe), or drugs acting on specific nuclear receptors involved in cholesterol and bile acid homeostasis, might be proposed as additional approaches for treating cholesterol gallstones. In this review we discuss old, recent and future perspectives on medical treatment of cholesterol cholelithiasis.

Entities:  

Keywords:  Bile; Bile acids; Cholecystectomy; Dissolution therapy; Ezetimibe; Gallbladder; Gallstones; Nuclear receptors; Statins

Year:  2012        PMID: 22577615      PMCID: PMC3348960          DOI: 10.4292/wjgpt.v3.i2.7

Source DB:  PubMed          Journal:  World J Gastrointest Pharmacol Ther        ISSN: 2150-5349


  156 in total

1.  Metabolic syndrome scientific statement by the American Heart Association and the National Heart, Lung, and Blood Institute.

Authors:  Scott M Grundy
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-11       Impact factor: 8.311

Review 2.  Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement.

Authors:  Scott M Grundy; James I Cleeman; Stephen R Daniels; Karen A Donato; Robert H Eckel; Barry A Franklin; David J Gordon; Ronald M Krauss; Peter J Savage; Sidney C Smith; John A Spertus; Fernando Costa
Journal:  Circulation       Date:  2005-09-12       Impact factor: 29.690

3.  Pain attacks in non-complicated and complicated gallstone disease have a characteristic pattern and are accompanied by dyspepsia in most patients: the results of a prospective study.

Authors:  Tewelde Berhane; Morten Vetrhus; Trygve Hausken; Snorri Olafsson; Karl Søndenaa
Journal:  Scand J Gastroenterol       Date:  2006-01       Impact factor: 2.423

4.  Small gallstones are associated with increased risk of acute pancreatitis: potential benefits of prophylactic cholecystectomy?

Authors:  Niels G Venneman; Erik Buskens; Marc G H Besselink; Susanne Stads; Peter M N Y H Go; Koop Bosscha; Gerard P van Berge-Henegouwen; Karel J van Erpecum
Journal:  Am J Gastroenterol       Date:  2005-11       Impact factor: 10.864

5.  Small gallstones, preserved gallbladder motility, and fast crystallization are associated with pancreatitis.

Authors:  Niels G Venneman; Willem Renooij; Jens F Rehfeld; Gerard P VanBerge-Henegouwen; Peter M N Y H Go; Ivo A M J Broeders; Karel J van Erpecum
Journal:  Hepatology       Date:  2005-04       Impact factor: 17.425

6.  Reduced susceptibility to cholesterol gallstone formation in mice that do not produce apolipoprotein B48 in the intestine.

Authors:  Helen H Wang; David Q-H Wang
Journal:  Hepatology       Date:  2005-10       Impact factor: 17.425

Review 7.  The metabolic syndrome.

Authors:  Robert H Eckel; Scott M Grundy; Paul Z Zimmet
Journal:  Lancet       Date:  2005 Apr 16-22       Impact factor: 79.321

Review 8.  Mechanisms of disease: the genetic epidemiology of gallbladder stones.

Authors:  Frank Lammert; Tilman Sauerbruch
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2005-09

9.  Ten years experience with piezoelectric extracorporeal shockwave lithotripsy of gallbladder stones.

Authors:  Thomas Rabenstein; Martin Radespiel-Tröger; Lutz Höpfner; Johannes Benninger; Michael Farnbacher; Holger Greess; Martin Lenz; Eckhart G Hahn; Hans T Schneider
Journal:  Eur J Gastroenterol Hepatol       Date:  2005-06       Impact factor: 2.566

10.  High cholesterol absorption efficiency and rapid biliary secretion of chylomicron remnant cholesterol enhance cholelithogenesis in gallstone-susceptible mice.

Authors:  David Q-H Wang; Lunan Zhang; Helen H Wang
Journal:  Biochim Biophys Acta       Date:  2005-01-06
View more
  24 in total

1.  Choledocholithiasis Without Cholelithiasis: Should the Gallbladder Stay or Should It Go?

Authors:  Pritesh Mutha; Tilak Shah; Douglas Heuman; Alvin Zfass; Mitchell L Schubert
Journal:  Dig Dis Sci       Date:  2016-04       Impact factor: 3.199

2.  Effects of sphincter of Oddi motility on the formation of cholesterol gallstones.

Authors:  Zhong-Hou Rong; Hong-Yuan Chen; Xin-Xing Wang; Zhi-Yi Wang; Guo-Zhe Xian; Bang-Zhen Ma; Cheng-Kun Qin; Zhen-Hai Zhang
Journal:  World J Gastroenterol       Date:  2016-06-28       Impact factor: 5.742

3.  Economic and medical benefits of ultrasound screenings for gallstone disease.

Authors:  Hung-Ju Shen; Chung-Te Hsu; Tao-Hsin Tung
Journal:  World J Gastroenterol       Date:  2015-03-21       Impact factor: 5.742

4.  The neglected cousin of the hepatocyte: how gallbladder epithelial cells might contribute to cholesterol gallstone formation.

Authors:  Arne Dikkers; Uwe J F Tietge
Journal:  Dig Dis Sci       Date:  2013-01-31       Impact factor: 3.199

Review 5.  Recent Advances in the Critical Role of the Sterol Efflux Transporters ABCG5/G8 in Health and Disease.

Authors:  Helen H Wang; Min Liu; Piero Portincasa; David Q-H Wang
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

6.  A novel GPER antagonist protects against the formation of estrogen-induced cholesterol gallstones in female mice.

Authors:  Chelsea DeLeon; Helen H Wang; Joseph Gunn; McKenna Wilhelm; Aidan Cole; Stacy Arnett; David Q-H Wang; Christopher K Arnatt
Journal:  J Lipid Res       Date:  2020-03-03       Impact factor: 5.922

Review 7.  Ursodeoxycholic acid therapy in gallbladder disease, a story not yet completed.

Authors:  Michele Pier Luca Guarino; Silvia Cocca; Annamaria Altomare; Sara Emerenziani; Michele Cicala
Journal:  World J Gastroenterol       Date:  2013-08-21       Impact factor: 5.742

8.  Spontaneous Cholelithiasis in a Squirrel Monkey (Saimiri sciureus).

Authors:  Mia T Lieberman; Lynn M Wachtman; Robert P Marini; Vasu Bakthavatchalu; James G Fox
Journal:  Comp Med       Date:  2016-02       Impact factor: 0.982

Review 9.  Epidemiology, management, and economic evaluation of screening of gallstone disease among type 2 diabetics: A systematic review.

Authors:  Lujie Chen; Yu-Ting Peng; Fu-Li Chen; Tao-Hsin Tung
Journal:  World J Clin Cases       Date:  2015-07-16       Impact factor: 1.337

10.  Protective effect of Glechoma hederacea extract against gallstone formation in rodent models.

Authors:  Min Xiao; Mengbi Yang; Xiaoyu Ji; Dan Li; Yuning Xie; Yuanfeng Lyu; Zhong Zuo
Journal:  BMC Complement Med Ther       Date:  2021-07-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.